EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Imaging-based classification of blood–brain barrier disruption in glioblastoma for patient selection in clinical trials: the NMN-BBB score

Nathalie L Albert, Roman Stürzl, Jonas Reis, Thomas Schabhüttl, Benedikte E Vindstad, Isabelle von Polenz, Maximilian J Mair, Katharina J Müller, Matthias Preusser

The Lancet Medical Imaging & Theranostics · 2026-08 · 1 (1) · 100002

DOI: 10.1016/j.lanmit.2026.100002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026-08. Verfasst von Nathalie L Albert und 8 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Servier.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The blood–brain barrier (BBB) limits the activity of novel treatments, such as pharmacotherapies and targeted radionuclide therapies in glioblastoma. Selection of patients with extensive tumoural BBB disruption might increase therapeutic efficacy. In a series of consensus-finding meetings, we conceptualised and developed a five-tiered scoring system to semi-quantitatively assess BBB disruption affecting metabolically active glioblastoma tissue based on the proportion of MRI contrast uptake within the amino acid PET-positive volume. The Nuclear Medicine and Neuro-Oncology (NMN)-BBB score ranges from 1 (the PET-positive volume shows no or minimal [ 90%] contrast enhancement). To describe the frequency of NMN-BBB score categories, we analysed neuroimages from a retrospective series of 343 patients with the following inclusion criteria: neuropathologically verified glioblastoma diagnosis, IDH -wild-type glioblastoma, newly diagnosed or recurrent disease, and availability of evaluable MRI and O-(2-[ 18 F]-fluoroethyl)-L-tyrosine-PET performed within 4 weeks of each other. We show that 31% (42 of 134) of newly diagnosed and 50% (104 of 209) of recurrent glioblastoma cases display an NMN-BBB score of 5, indicating a high extent of BBB breakdown throughout viable tumour tissue. We believe the application of the NMN-BBB score might facilitate the development of novel therapies through refining patient selection and should be considered for implementation in clinical trial protocols.

Förderung

  • Servier

Zitieren

APA

Albert, N. L., Stürzl, R., Reis, J., Schabhüttl, T., Vindstad, B. E., Polenz, I. V., Mair, M. J., Müller, K. J., & Preusser, M. (2026). Imaging-based classification of blood–brain barrier disruption in glioblastoma for patient selection in clinical trials: the NMN-BBB score. The Lancet Medical Imaging & Theranostics, 1(1), 100002. https://doi.org/10.1016/j.lanmit.2026.100002

Vancouver

Albert NL, Stürzl R, Reis J, Schabhüttl T, Vindstad BE, Polenz IV, et al. Imaging-based classification of blood–brain barrier disruption in glioblastoma for patient selection in clinical trials: the NMN-BBB score. The Lancet Medical Imaging & Theranostics. 2026;1(1):100002. doi:10.1016/j.lanmit.2026.100002

BibTeX
@article{Albert2026,
  author = {Albert, Nathalie L and Stürzl, Roman and Reis, Jonas and Schabhüttl, Thomas and Vindstad, Benedikte E and Polenz, Isabelle von and Mair, Maximilian J and Müller, Katharina J and Preusser, Matthias},
  title = {Imaging-based classification of blood–brain barrier disruption in glioblastoma for patient selection in clinical trials: the NMN-BBB score},
  journal = {The Lancet Medical Imaging & Theranostics},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {100002},
  doi = {10.1016/j.lanmit.2026.100002}
}
Kostenlos starten →